The store will not work correctly when cookies are disabled.
We use cookies for optimal website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.
Allow cookies Deny
7-nitroisoquinolin-4-amine; CAS No.: 1936476-62-8;7-nitroisoquinolin-4-amine. PROPERTIES: 7-nitroisoquinolin-4-amine is a heterocyclic aromatic compound with molecular formula C9H6N2O2. This crystalline solid exhibits typical properties of aromatic amines with a nitro group substituent. The 7-nitroisoquinolin-4-amine compound has a melting point ranging between 185-190 C and is moderately soluble in common polar solvents like dimethyl sulfoxide and dimethylformamide while showing limited solubility in water. The nitro group imparts strong electron-withdrawing characteristics, influencing the compound's reactivity and stability. Proper storage requires a tightly sealed container in a cool, dark environment below 20 C to prevent degradation. Safety precautions include using N-95 respiratory protection during handling, as the compound may pose inhalation hazards. Skin and eye contact should be avoided due to potential irritation. According to GHS standards, the compound carries H302+H312+H332 hazard statements for harmful effects via various exposure routes. APPLICATIONS: The 7-nitroisoquinolin-4-amine structure serves as a key intermediate in pharmaceutical synthesis pathways. In medicinal chemistry, it acts as a building block for developing isoquinoline-based alkaloid mimetics, as reported in heterocyclic chemistry journals. The compound's nitro group can be reduced to an amine functionality, enabling diverse synthetic transformations. Additionally, 7-nitroisoquinolin-4-amine derivatives have been investigated for their biological activities, particularly in antimicrobial and anticancer screening assays documented in medicinal research publications. The isoquinoline scaffold forms the basis for several FDA-approved medications, highlighting its importance in drug discovery pipelines according to pharmaceutical industry reports.